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Hepatitis C virus/human immunodeﬁciency virus (HCV/HIV) coinfected patients demonstrate acceler-
ated progression to severe liver injury in comparison to HCV monoinfected patients, although the
underlying mechanisms are unclear owing to infection of separate tissue compartments with two
distinct viral pathogens. Microarray analysis of paired liver biopsy and peripheral blood mononuclear
cell (PBMC) specimens from HCV/HIV coinfected and HCV monoinfected patients identiﬁed a gene
expression signature associated with increased inﬂammation and immune activation that was present
only in liver and PBMC samples from coinfected patients. We also identiﬁed in these samples liver- and
PBMC-speciﬁc signatures enriched with ﬁbrogenic/hepatic stellate activation and proinﬂammatory
genes, respectively. Finally, Bayesian networks were constructed by assimilating these data with
existing data from liver and PBMC samples from other cohorts, augmenting enrichment of biologically
important pathways and further indicating that chronic immune activation in HCV/HIV coinfection may
exacerbate liver disease progression in coinfected patients.
& 2012 Elsevier Inc. All rights reserved.Introduction
Chronic HCV infection may lead to severe hepatic injury,
including ﬁbrosis, cirrhosis, and hepatocellular carcinoma (HCC).
Liver disease typically progresses slowly, with severe disease
developing over 10–30 years following HCV infection. However,
human immunodeﬁciency virus (HIV) coinfection can profoundly
impact the natural history of HCV infection. Several studies have
demonstrated that HCV/HIV coinfected patients exhibit increased
hepatic inﬂammation (Di Martino et al., 2001; Martinez-Sierra
et al., 2003; Pol et al., 1998), and progress more rapidly to severe
liver disease (Graham et al., 2001; Soto et al., 1997) in comparison
to HCV-monoinfected patients. Due to the effectiveness of highly
active antiretroviral therapy (HAART), the incidence of HIV
progression to acquired immune deﬁciency syndrome (AIDS)ll rights reserved.
atze).
.
Blaine Street, Seattle,has been dramatically decreasing. However, HCV/HIV-coinfected
patients are increasingly experiencing morbidity and mortality
associated with HCV-induced liver disease.
The mechanisms underlying rapid liver disease progression in
HCV/HIV co-infected patients are poorly understood and are
likely multifactorial. Contributing factors which may accelerate
liver disease progression include HIV-associated immune dys-
function (Gonzalez et al., 2009b; Sandberg et al., 2010), oxidative
stress (Baum et al., 2011; Lin et al., 2011; Wanchu et al., 2009),
apoptosis (Jang et al., 2011), enhanced HCV replication (Lin et al.,
2008), viral modulation of cytokine/chemokine responses (Allison
et al., 2009), and HIV infection or activation of resident liver cells
such as hepatic stellate cells or Kupffer cells (Tuyama et al., 2010).
Unfortunately, no widely accepted experimental model of HCV/
HIV coinfection is currently available. Therefore, detailed studies
of liver disease pathogenesis have been limited, and are restricted
to clinical samples.
Previously, we analyzed liver biopsies from HCV mono- and
HCV/HIV coinfected patients and identiﬁed gene expression
signatures indicative of dysregulation of apoptosis, increased
immune cell activation, and decreased innate antiviral responses
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However, a speciﬁc intrahepatic signature distinguishing HCV/
HIV coinfected from HCV monoinfected patients was not identi-
ﬁed. In this study, we utilized core needle liver biopsies and a
whole genome microarray with over twice the human transcrip-
tome coverage of those used previously to identify intrahepatic
gene signatures speciﬁcally associated with HCV/HIV. We also
explored previous observations that HCV mono- and HCV/HIV
coinfection induce unique immunologic gene expression proﬁles
in peripheral mononuclear blood cells (PBMC) (Kottilil et al.,
2009). In addition to liver biopsy specimens, PBMCs from the
same subjects were evaluated by microarray to investigate how
transcriptional programming of immune cells in the periphery
might contribute to hepatic inﬂammation, cellular inﬁltration,
and disease progression.
Expression proﬁling of clinical specimens can prove challen-
ging due to numerous confounding variables, limitations on
sample sizes, and heterogeneous subject characteristics. In an
attempt to mitigate some of these challenges, and to expand the
scope of our functional analysis, we used our transcriptomic data
to construct Bayesian networks in conjunction with published
liver (Lamb et al., 2011; Schadt et al., 2008; Zhong et al., 2010)
and PBMC gene expression data (Emilsson et al., 2008) obtained
from larger independent cohorts. These networks allowed us to
identify additional genes in critical pathways functionally asso-
ciated with HCV/HIV co-infection, enhancing our understanding
of the complex biology of liver disease progression in HCV/HIV
coinfected patients.Results
Subject characteristics
Demographic and clinical characteristics of the subjects are
shown in Table 1. In total, 10 HCV monoinfected and 13 HCV/HIV
coinfected patients were recruited in this study. The two groups
were well-matched for age, ethnic background, body mass index
(BMI), duration of HCV infection, alcohol use, serum ALT levels,
HCV genotype, HCV viral load, and Batts–Ludwig liver disease
stage. The HCV/HIV coinfected group was predominantly maleTable 1
Characteristics of HCV-infected subjects.
HIV-ne
Age 47.277
Gender (% male) 60
Race (%)
Caucasian 90
African American 10
Native American 0
HCV duration (years) 24.577
Alcohol use in lifetime (gm/d) (median, IQR) 24.1, 40
Alcohol use in last 6 months (gm/d) (median, IQR) 0, 0
ALT (U/L) 92750
HCV genotype (% 1) 80
HCV RNA level (log 10) 6.27 .5
Antiretroviral therapy (%) NA
HIV RNA level (log 10)a NA
HIV RNA level, % undetectable (o400 copies/mL) NA
CD4 cell count (cells/mL) 11207
HCV disease grade (0–4)b 2.57 .7
HCV disease stage (0–4)b 2.17 .3
Values expressed as mean7SD unless stated otherwise. NA, not applic
a In those with detectable virus.
b Batts–Ludwig scoring system.(92%) and demonstrated signiﬁcantly lower CD4 T cell counts
(mean 451 versus 1120, p¼ .0014) compared to the HCV mono-
infected group. Also, the majority of coinfected patients (77%)
received anti-retroviral treatment, which likely contributed to the
lack of detectable HIV RNA in 63% of the subjects. Both groups
were naı¨ve to HCV therapy. Seventy percent of the subjects
reported abstinence from alcohol use for at least one year prior
to enrollment. We also performed a correlation analysis to assess
which clinical parameters might confound our gene expression
results, and identiﬁed HIV status and consequent CD4 cell counts
as the only parameters signiﬁcantly inﬂuencing gene expression
(data not shown). It is likely that the correlation with CD4 T cell
counts reﬂects the lower counts observed in the HIV-positive
subjects. Due to the limited sample size, a multivariate analysis
was not performed. We speciﬁcally did not ﬁnd any association
between gene expression and other HIV-speciﬁc covariates such
as serum HIV quantitation (suppressed or not) and the use of
antiretroviral therapy, though we note that in this study, these
patient subgroups are too small to perform a statistically robust
correlation analysis.
Common transcriptional signatures in liver and PBMC samples from
HCV/HIV coinfected patients
Using a two-way ANOVA approach, a molecular signature
common to liver and PBMC samples from coinfected patients was
identiﬁed. A total of 467 upregulated and 338 downregulated
differentially expressed genes (DEG; po .01) were identiﬁed in
both samples (Fig. 1A; Table S1). Common differential expression
in both liver and PBMC may indicate that these pathways are
comparably regulated separately in both tissues, and/or that
many PBMC have migrated into and substantially contribute to
the overall gene expression proﬁle in liver. Functional analysis
was performed on the 805 DEG common to both tissues using
Ingenuity Pathway Analysis (IPA). Many of the top functional
categories among the upregulated genes were associated with
inﬂammation, indicating that distinct mechanisms may drive
progression of hepatic inﬂammation in coinfected patients.
Among 84 upregulated genes associated with inﬂammatory and
immunological responses and disease (Table S1), we observed
DEG associated with components of complement, chemokines,gative (n¼10) HIV-positive (n¼13) P value
.5 42.677.8 .18
92 .06
.44
69
23
7.7
.8 22.0711.0 .57
.7 17.0, 46.9 .80
0, .9 .45
68736 .23
77 .86
6.371.0 .60
77 –
4.57 .7 –
54 –
471 4517292 .0014
1.87 .8 .05
2.171.0 .9
able; IQR, interquartile range.
H
C
V
H
C
V
/H
IV
H
C
V
H
C
V
/H
IV
Li
ve
r
P
B
M
C
131
133
138
140
144
145
149
151
154
96
107
122
126
127
130
134
139
141
143
147
152
124
156
131
133
138
140
144
145
151
149
154
96
107
122
126
127
130
134
139
141
143
147
152
124
156
patient id
Log (Ratio)
-0.19 0.190
Fig. 1. Common gene signature distinguishing HCV/HIV coinfected patients. (A) Heatmap of 805 signiﬁcant differentially expressed genes in liver and PBMC from HCV/HIV
coinfected patients compared to HCV monoinfected as determined by two-way ANOVA (po .01). (B) IPA network showing connected genes related to immune cell
migration and inﬂammation from the common signature.
A.L. Rasmussen et al. / Virology 430 (2012) 43–52 45and antigen presentation and T cell activation (Fig. 1B). The
presence of gene expression changes associated with immune
activation and migration may indicate enhanced trafﬁcking of
activated immune effector cells from the periphery to the liver in
HCV/HIV coinfected patients.Identiﬁcation of hepatic signatures of coinfection
We also sought to identify signiﬁcant hepatic DEG character-
istic of HCV/HIV coinfected patients. Using one-way ANOVA
(po .05, fold change 41.15 in at least 7 samples), we identiﬁed
A.L. Rasmussen et al. / Virology 430 (2012) 43–5246transcriptional signatures in the coinfected patient cohort using
microarray data from liver samples only (Fig. 2A; Table S2).
Functional analysis by IPA demonstrated that in liver samplesLi
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Fig. 2. Compartmental gene signatures distinguishing HCV/HIV coinfected patients. (A
identiﬁed by one-way ANOVA (po .05, fold change 41.15 in at least 7 patients) and se
directly connected molecules associated with inﬂammation and immunity.from coinfected patients, over 250 genes related to infectious
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A.L. Rasmussen et al. / Virology 430 (2012) 43–52 47functionally similar to those identiﬁed in the common signature,
and are associated with chemotaxis and cellular migration,
including various chemokines, integrins (ITGAD, ITGA5, ITGA7,
ITGB2), actin and tubulin cytoskeletal components (ACTB, ACTG,
TUBA1A, TUBA1C, TUBA4A, TUBG1), and multiple Ras-like homo-
log members and related genes [RHOA, RHOB, RHOD, RHOG,
RHOQ, Ras-related C3 botulinum toxin 1, rho family small GTP
binding protein 1 (RAC1)] involved in the recruitment of circulat-
ing immune cells to the liver. Many DEG associated with T cell
activation processes, including human leukocyte antigens
(HLA-DQA1, HLA-DQB1) that mediate antigen presentation, mole-
cules associated with dendritic cell (DC) maturation (CD209), and
T cell receptor signaling machinery (CD3, CD8A) were upregu-
lated. This suggests that the T cells inﬁltrating the liver in
coinfected patients may be transcriptionally distinct from T cells
of HCV monoinfected patients, and may have a more activated
phenotype due to chronic HIV infection. The substantial overlap
(286 genes) between the hepatic signature and the signature
common to both liver and PBMC (identiﬁed using two-way
ANOVA) supports an important contributing role for inﬁltrating
immune cells within the livers of coinfected patients.
We further observed the upregulation of genes functionally
linked to hepatic stellate cell (HSC) activation including the Rho
family GTPases, actins, myosin light chain 6 (MYL6), and cell
division cycle 42 (CDC42), a major regulator of cytoskeletal
remodeling previously associated with chronic liver injury and
tumorigenesis (van Hengel et al., 2008) and HCV-induced hepatic
ﬁbrosis (Smith et al., 2003). This network of molecules (Fig. 2B)
links activation of HSCs, inﬂammatory signaling, and immune cell
inﬁltration. We also identiﬁed several secreted factors that con-
nect activated macrophages and Kupffer cells to HSC activation,
including platelet-derived growth factor receptor, alpha polypep-
tide (PDGFRA) and vascular endothelial growth factor (VEGF), and
the chemokines CCL2, CXCL3, CCL13, and CCL5. Additionally,
genes known to be expressed by activated HSCs, such as Bcl-2
associated X (BAX), which are also related to chemoattraction and
apoptotic induction were upregulated. This contrasts with the
downregulation of genes associated with inhibition of apoptosis
(such as baculovirus IAP repeat-containing 5 [BIRC5]) and cell
cycle progression (such as p21-activated kinase 7 [PAK7] and
kinesin family member 11 [KIF11]) and is consistent with a report
that HSC apoptosis is anticorrelated with HCV-induced ﬁbrogen-
esis (Gonzalez et al., 2009a). Taken together, these ﬁndings
suggest that in HCV/HIV coinfected patients, increased migration
of activated immune effector cells likely contributes to increased
hepatic inﬂammation. This in turn may lead to increased HSC
activation, hastening collagen deposition and ﬁbrogenesis and
possibly contributing to more rapid liver disease progression in
HCV/HIV coinfected patients.Reg3α 14 kDa
Reg1α 14 kDa
Reg1α 20 kDa
Fig. 3. Expression of Reg1a and Reg3a proteins. Immunoblot analysis of Reg1a
and Reg3a protein in patient plasma specimens. Molecular weight of the detected
Reg1a and Reg3a proteins are indicated on the left side of the ﬁgure. Reg1a is
detected in the 14–22 kDa range, consistent with differential proteolytic proces-
sing and/or glycosylation heterogeneity observed as a result of proteolytic
processing and differential glycosylation than monoinfected patients. Addition-
ally, a higher molecular weight band at approximately 20 kDa represents either
the precursor form of Reg1a or one of the other glycosylated isoforms of this
protein reported within the 17–22 kDa size range (De Reggi et al., 1995) present in
all samples.Identiﬁcation of peripheral signatures of coinfection
In the PBMC compartment, functional analysis using IPA
revealed that many of the upregulated genes were associated
with immune induction and immunological disease. Speciﬁcally,
271 genes associated with inﬂammatory responses, antigen pre-
sentation, and humoral immune responses, as well as hematolo-
gical, immunological, and inﬂammatory disease were signiﬁcantly
upregulated (Table S3). Genes within this group include chemo-
kine receptors and other molecules associated with chemotaxis
and lymphocyte homing including the HIV receptor CCR5, com-
plement components, and proinﬂammatory cytokines associated
with T cell activation such as IL-11, IL-17RA, and IL-15. Addition-
ally, we observed numerous gene expression changes associated
with antigen presentation and CD4 T cell activation, includingupregulation of the genes encoding costimulatory molecules
CD86 and numerous HLA alleles. The molecular signature also
featured concomitant downregulation of genes known to sup-
press T cell activation, such as cytotoxic T lymphocyte-associated
protein 4 (CTLA-4). These are consistent with the chronic activa-
tion of HIV-infected T cells.
Interestingly, we also identiﬁed a subset of transcripts asso-
ciated with ﬁbrosis and extracellular matrix deposition upregu-
lated in HCV/HIV coinfected PBMC, including several types of
collagen (COL22A1, COL3A1, COL4A1) and galectins (LGALS1,
LGALS3, LGALS8). Notably, both galectin-1 and galectin-3 have
been implicated in HSC activation and hepatic ﬁbrogenesis
(Henderson et al., 2006; Jiang et al., 2011; Maeda et al., 2003),
as have Rho GTPases and rearrangement of the actin cytoskeleton
(Kato et al., 1999). Circulating PBMC in HCV/HIV coinfected
patients thus display increased ﬁbrogenic gene expression, and
may subsequently enhance HSC activation and collagen deposi-
tion upon immune inﬁltration of the liver.
Overexpression of REG1A and REG3A secreted proteins
In addition to evaluating the global DEG signature associated
with HCV/HIV coinfection, we sought to identify molecules highly
expressed by the liver which may be candidates for evaluation
as potential therapeutic or diagnostic targets. From DEG in the
intrahepatic signature, we observed that regenerating islet-
derived 1 alpha and 3 alpha (REG1A and REG3A) were among
the most highly upregulated in a subset of 7 patients. Reg1a and
Reg3a are both secreted growth factors associated with pancrea-
tic islet cell regeneration, which were previously linked to a
number of gastrointestinal cancers, including hepatocellular car-
cinoma (Cavard et al., 2006; Yuan et al., 2005). Reg1a and Reg3a
accelerate liver regeneration (Lieu et al., 2005; Wang et al., 2009),
and Reg3a has been implicated in the activation of pancreatic
stellate cells, as well as deposition of collagen and associated
extracellular matrix components (Li et al., 2009), suggesting that
these molecules may be linked to liver disease progression.
Therefore, we evaluated whether or not these molecules might
have potential as prognostic indicators of HCV/HIV coinfection-
associated liver disease.
By assessing Reg1a and Reg3a levels in patient plasma speci-
mens by immunoblot (Fig. 3), we observed that HCV/HIV patients
exhibited substantially higher levels of circulating Reg1a species
compared to monoinfected individuals. In particular, a higher
molecular weight form of Reg1a corresponding to either a precursor
A.L. Rasmussen et al. / Virology 430 (2012) 43–5248form or a heavily glycosylated protein, was consistently expressed at
higher levels. Secreted Reg3a levels were not signiﬁcantly different
between the two patient conditions, although Reg3a was detectable
in all tested samples. This suggests that the higher molecular weight
form of circulating Reg1a may be a candidate for evaluating hepatic
disease progression by a non-invasive, blood-based study, and
warrants further evaluation.
Expanding co-infected liver and PBMC signatures by a network
approach
The cross-sectional design of this study restricted detection of
liver and PBMC signature DEG to one time point. To identify
additional genes which may contribute to liver disease progres-
sion in the coinfected tissues, we adopted a Bayesian network
modeling approach to predict interactions between signiﬁcant
DEG in our study and those in networks built from previously
published large data sets. Bayesian networks represent statistical
dependencies between genes (‘‘nodes’’) as ‘‘edges,’’ which are
calculated by multiple expression measurements. Leveraging
networks generated from much larger datasets can increase the
robustness of biological ﬁndings from a smaller dataset by further
exploring the interrelated connectivity of DEG found in lower
abundance.
Combined replicates of liver signature sequences were used as
the input to Bayesian networks built from three human liver
cohorts including 400 normal samples (Schadt et al., 2008), 272
samples each of hepatocellular carcinoma (HCC) and adjacent
normal livers (Lamb et al., 2011), and 950 livers from obese
subjects (Zhong et al., 2010). Out of the 2442 liver signature
sequences, 924 genes were present in the three liver networks but
only those subnetworks with at least 3 nodes (290 genes) were
maintained. In subnetworks meeting these criteria, we expanded
along one edge to identify additional connected nodes and obtain
the network shown in Fig. 4A with 2544 genes.
We performed functional analysis of this liver network by
using the Gene Annotator Module of the Merck Target Gene
Information (TGI) Network Analysis and Visualization (NAV) tool,
which ﬁnds related gene sets based on functional annotation, and
ranks signiﬁcance by calculating an expectation (E) value. Our
analysis identiﬁed highly enriched pathways involved in chemo-
kine signaling, dendritic cell maturation, interaction between
innate and adaptive immunity, T cell receptor signaling, pattern
recognition receptor-related pathway, NK cell signaling, and
hepatic cholestasis/ﬁbrosis (Table S4). This suggests that the
genes added by the network analysis are related to cross-talk
between the innate and adaptive immune system, and the inter-
face between these different immune pathways may play an
important role in HCV/HIV coinfection.
We identiﬁed similar functional categories and pathways using
IPA. Some of these overlap with those already identiﬁed in Fig. 1B
whereas others are novel pathways found to be associated with
this liver network. Using IPA, we generated a subnetwork using
the genes annotated as involved in communication between
innate and adaptive immune cells (Fig. 4B). This subnetwork
includes additional genes related to induction of innate antiviral
responses (multiple Toll-like receptors; TLR) and inﬂammation
(tumor necrosis factor alpha; TNFa), as well as induction of
adaptive immunity via antigen presentation (HLA alleles) and T
cell activation (CD3, CD8).
We built a PBMC network model using the similar approach of
inputting 2479 combined replicate signature sequences to the
deCODE blood Bayesian network built from about 1000 samples
(Emilsson et al., 2008). We applied similar criteria as the liver
network, maintaining only 131 genes (out of 561 present in the
deCODE network) in sub-networks with at least 3 nodes and grewthem one edge out to obtain a network with 1117 genes.
Annotation of genes in this PBMC network indicates an associa-
tion with T and B cell signaling, interaction between dendritic and
natural killer cells, and communication between innate and
adaptive immune cells (Table S4). These results are consistent
with ﬁndings shown in Fig. 1B, and suggest that PBMC from
coinfected patients exhibit the differential regulation of genes
bridging innate and adaptive immunity.Discussion
Understanding disease pathogenesis in HCV/HIV coinfected
patients presents numerous challenges, one of which is discerning
how distinct tissue compartments infected with two unique
pathogens contribute separately and in concert to liver disease
progression. Our data suggest that the chronic immune activation
characteristic of HIV infection and progression to AIDS (Deeks
et al., 2004; Hazenberg et al., 2003) is a distinguishing feature of
the host response to HCV/HIV coinfection. We observed substan-
tial overlap (104 DEG, 24 of which are associated with immune
activation and differentiation) between both the individual liver
and PBMC compartments and the signature common to both
tissues. This further supports the notion that increased immune
and inﬂammatory activity are present in both the liver and the
periphery of coinfected patients and are likely important drivers
of disease pathogenesis. The enhanced expression of inﬂamma-
tory genes in both the common and individual compartment
signatures suggests that HIV infection causes both circulating
leukocytes, and those inﬁltrating the liver, to be more activated
than those from HCV monoinfected patients. Consequently, the
pro-inﬂammatory functions of these cells may enhance patho-
genic processes and progression of ﬁbrosis and HCV-induced liver
injury via immune effector functions, cytokine and chemokine
secretion, increased migration, and activation of HSC and other
cellular mediators of ﬁbrogenesis.
Another effect of HIV-infected inﬁltrating immune cells on
HCV-infected hepatic cells may be to stimulate expression of
genes with as yet undescribed roles in liver disease progression.
The growth factors Reg1a and Reg3a have not been associated
with HCV or HIV infection or pathogenesis. However, their
apparent role in HCC tumorigenesis and metastasis (Cavard
et al., 2006; Yuan et al., 2005), as well as our data indicating that
these proteins are secreted, merits further evaluation of these
proteins in a larger patient cohort as serum biomarkers with
prognostic or diagnostic utility.
Recent systems biology approaches incorporating high-through-
put data types, such as genome-wide DNA genotyping and RNA
expression proﬁling, has allowed the construction of various types of
genetic networks. Characterizing networks that underlie complex
phenotypes such as clinical disease can provide more comprehensive
understanding of the disease pathophysiology and in turn identify or
validate disease susceptibility genes (Chen et al., 2008; Derry et al.,
2010; Emilsson et al., 2008; Schadt et al., 2008; Yang et al., 2009). In
the current study, the gene signatures we obtained were from a
single time point (at which disease progression could be hetero-
geneous) and from a relatively small number of patients. In an effort
to address these constraints and expand potential biological cover-
age, we used coinfected liver and PBMC gene signatures to build
Bayesian statistical causal networks based on published large liver
and blood data sets (Emilsson et al., 2008; Lamb et al., 2011; Schadt
et al., 2008; Zhong et al., 2010). From these networks, we obtained
greater enrichment based on functional annotation for the resulting
liver network (Fig. 4A and Table 2) and the PBMC network (Fig. 4B
and Table 2) compared to our functional analysis using the signiﬁ-
cant DEG identiﬁed in this study alone. These expanded networks
Antigen Presentation
T Cell Activation
TLR Signaling
Chemotaxis
Inflammation
Fig. 4. Construction of HCV/HIV co-infected liver Bayesian network. (A) Liver network was constructed by overlaying 2442 liver signature sequences onto the network
formed from 3 existing liver cohorts as described in the Materials and Methods section. Only those sub-networks with at least 3 connected nodes (290 genes) were
retained to grow one edge out to obtain the network shown with 2544 genes. (B) Liver subnetwork of genes annotated as those involved in communication between innate
and adaptive immune cells. Solid lines show directly interacting molecules, dashed lines show indirect interactions. Upregulated genes identiﬁed in the common signature
in this study are colored yellow; genes identiﬁed in the network model are colored green. (For interpretation of the references to color in this ﬁgure legend, the reader is
referred to the web version of this article).
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HIV coinfected liver and PBMC molecular signatures, and provided
greater insight into functionally related genes that might also be
signiﬁcant for liver disease pathogenesis in a larger population of
HCV/HIV coinfected patients.NK cells and DCs mediate both effector and regulatory functions
in innate immunity and the induction of adaptive responses (Altfeld
et al., 2011; Gonzalez et al., 2010; Kim and Chung, 2009); however,
the HCV/HIV coinfected liver signature did not capture these
functions as signiﬁcantly associated with coinfection (Fig. 1B). The
Table 2
Pathways and genes identiﬁed for expanded networks.
TGI NAV pathways Expectation Set Genes identiﬁed in network
Liver network
Chemokine signaling
pathway
1.587E16 189 CCL4;CXCR4;GNB5;PRKCB;AKT2;PRKX;CCR1;CXCR3;CCL14;GNG11;PLCB2;CCL11;PIK3R1;
CCL4L1;GRK5;FOXO3;STAT3;CCL2;CRK;RAC2;PIK3CB;ELMO1;CXCL1;IL8;CCL19;CCL5;
DOCK2;CCL15;CXCR2;ADCY7;ITK;CXCL16;PIK3CG;PIK3CA;CDC42;CXCR6;PRKACB;CCL23;
CXCL6;ROCK1;PIK3R5;CCL4L2;HCK;CCR6;GNB1;VAV3;GNB4;MAP2K1;CXCL3;CCL8;CXCL12;
GNG2;CCL3;ARRB1;PREX1;GRK4;CCL13;SHC1;CXCR1;ADCY1
Dendritic cell maturation 4.411E14 148 IL6;CD86;REL;CD247;CD83;COL1A2;FCER1G;AKT2;HLA-DRB1;STAT4;TLR2;LTBR;CREB5;
TRGV9;PIK3R1;FCGR1A;FCGR2B;HLA-DMB;TLR4;IL18;TYROBP;RAC2;PIK3CB;TNFRSF11B;
HLA-DQB1;FCGR3B;HLA-DMA;B2M;HLA-DRB5;PIK3CG;PIK3CA;CD3E;RELB;NFKBIE;
HLA-DRA;FCGR3A;TNF;HLA-B;PIK3C2G;PIK3R5;FCGR1B;CD3D;TNFRSF1B;
CD58;IL1B;LY75;HLA-DRB3;FCGR2A;IRF8
Communication between
innate and adaptive
immune cells
6.31E12 68 IL6;CD86;CCL4;CD247;CD83;FCER1G;HLA-DRB1;TLR2;TRGV9;TLR4;IL18;CD4;IL8;CCL5;
CCL15;HLA-DRB5;CD8A;CD3E;TLR1;HLA-DRA;TNF;CD3D;TLR8;IL1B;CCL3;
HLA-DRB3;TNFSF13B;CD8B;IFNG;CD28
iCOS-iCOSL signaling in T
helper cells
2.962E11 100 INPP5D;REL;CD247;IL2RB;NFAT5;FCER1G;AKT2;PRKCQ;HLA-DPB1;TRGV9;PIK3R1;
HLA-DMB;CD4;RAC2;LCP2;PIK3CB;IL2RA;HLA-DMA;ITK;HLA-DRB5;PIK3CG;PIK3CA;
CD3E;RELB;NFKBIE;PPP3R1;TRAT1;PIK3C2G;PIK3R5;PTPRC;CD3D;ICOS;LCK;
HLA-DRB3;SHC1;CD28
Natural killer cell
signaling
6.527E08 103 INPP5D;CD247;PRKCB;FCER1G;AKT2;PRKCQ;
SYK;PIK3R1;FYN;LILRB1;KLRK1;TYROBP;RAC2;
LCP2;PIK3CB;CD244;FCGR3B;PIK3CG;PIK3CA;SH2D1A;FCGR3A;KLRB1;PIK3C2G;PIK3R5;
VAV3;LAIR1;MAP2K1;SIGLEC7;LCK;SHC1;CD300A;HCST
PBMC network
Altered T Cell and B Cell
signaling in
rheumatoid arthritis
.002 80 CD86;FCER1G;TNFSF11;TLR2;FAS;CCL21;CD40LG;HLA-DMA;IL23A;LTB;TLR5;IL1B;IFNG;CD28
Crosstalk between
dendritic cells and
natural killer cells
.002 92 CD86;CCR7;KIR3DL2;FAS;KLRK1;TYROBP;CD40LG;TLN1;LTB;TNFSF10;CD209;TREM2;
PRF1;IFNG;CD28
Communication between
innate and adaptive
immune cells
.008 68 CD86;CCR7;FCER1G;TLR2;CD40LG;CCL5;CD8A;TLR5;IL1B;CD8B;IFNG;CD28
Role of macrophages
ﬁbroblasts and
endothelial cells in
rheumatoid arthritis
.014 294 PRSS35;LRP1;HP;PRKCH;FN1;TNFSF11;TLR2;CALM3;CREB5;PDGFD;TCF7;SFRP4;NFATC2;
CCL5;LTB;PRKCA;MYC;IL6ST;KRAS;GNAQ;CAMK4;IL32;TLR5;OSM;IL1B;C5AR1;MAP2K3;LEF1
A.L. Rasmussen et al. / Virology 430 (2012) 43–5250expanded liver network, however, did identify signiﬁcant associa-
tions with NK and DC functions (Table 2). Innate immunity-
associated genes present in the network, but not in the co-infected
liver signature, include TLR1, TLR2, TLR4, and TLR8. TLR signaling
provides a critical link between innate and adaptive immunity in
numerous viral infections. In chronic HCV infection, reduced TLR
responsiveness is associated with liver dysfunction (Chung et al.,
2011) and chronic inﬂammation consequent to reduced induction
of adaptive immune responses (Dental et al., 2012; Yonkers et al.,
2011b). Furthermore, aberrant TLR signaling has been implicated
in T cell activation defects in HIV infection (Yonkers et al., 2011a),
indicating that these molecules may be important mediators of
chronic immune activation and inﬂammation in the HCV/HIV
coinfection setting. In addition, the liver network (Table 2) includes
some key ﬁbrogenic genes such as transforming growth factor-b1,2,
and 3 (TGFB1, TGFB2 and TGFB3), which have been implicated both
in Rho GTPase-mediated HSC activation (Shimada et al., 2011) and
enhancement of HCV replication and associated liver injury (Lin
et al., 2008).This network allowed us to bridge gaps present in the
molecular signatures from our dataset, and establish a more
comprehensive expression proﬁle characteristic of liver disease
pathogenesis in HCV/HIV coinfection.
The observed host transcriptional signatures and networks
characteristic of liver and/or PBMC in HCV/HIV coinfected patients
indicate that these compartments are distinguished by increased
immune activation consistent with HIV infection. This environ-
ment may in turn contribute to increased hepatic upregulation of
pro-ﬁbrogenic genes, and reveals a possible mechanism for theaccelerated liver disease progression observed in coinfected
patients. Future studies employing longitudinal samples from a
larger patient cohort should be directed at understanding how
these genes are temporally regulated throughout the course of liver
disease progression. Additionally, follow up studies should deter-
mine the clinical utility of potential biomarkers such as Reg1a to
identify patients at risk of accelerated severe liver injury.Materials and methods
Study subjects and specimen collection
Approval for this study was obtained from the University of
Washington Human Subjects Division, and experiments were
performed in compliance with legal, institutional, and ethical
standards for human subjects research. All samples were obtained
under informed consent.
Ten subjects infected with HCV and 13 subjects coinfected
with HCV and HIV were included in this study. Exclusion criteria
included chronic hepatitis B infection, alcohol use 41 drink per
day in women and 42 drinks per day in men, and acute infection
of any type. An experienced hepatopathologist (L.V.T.) blinded to
all clinical data including HIV status reviewed all liver biopsies.
Liver ﬁbrosis stage was assessed using the Batts–Ludwig system:
F0, no ﬁbrosis; F1, portal ﬁbrosis; F2, periportal ﬁbrosis with rare
bridges; F3, bridging/septal ﬁbrosis; or F4, cirrhosis (Batts and
Ludwig, 1995). All samples included were deemed adequate for
A.L. Rasmussen et al. / Virology 430 (2012) 43–52 51staging. At the time of liver biopsy, 2–3 mm of liver tissue was
stored in RNALater (Life Technologies, Mountain View, CA) at 4 1C
overnight, and then stored at 80 1C until RNA processing. Whole
blood was obtained by venipuncture within 30 day of the liver
biopsy (typically within one week of the biopsy). Peripheral blood
mononuclear cells (PBMCs) were isolated by Ficoll density cen-
trifugation (Ficoll-Paque Plus; GE Healthcare Biosciences, Piscat-
away, NJ) within 24 h of blood draw, and 2106 freshly isolated
PBMC were pelleted and resuspended in Trizol (Life Technologies,
Carlsbad, CA) prior to ﬂash freezing in liquid nitrogen. Samples
were stored at 80 1C until RNA was prepared according to the
manufacturer’s instructions. Samples were extracted according to
manufacturer’s protocol and resuspended in RNAse-free water
prior to use in microarray experiments.Microarray platform
Samples were ampliﬁed and labeled using a custom auto-
mated version of the RT/IVT protocol and reagents provided by
Affymetrix. Hybridization, labeling and scanning were completed
following the manufacturer’s recommendations using Merck
Affymetrix Human Custom Arrays 1.0 containing 43,737 unique
probe sequences (Affymetrix, Santa Clara, CA). Sample ampliﬁca-
tion, labeling, and microarray processing were performed by the
Rosetta Inpharmatics Gene Expression Laboratory in Seattle,
WA (acquired by Merck and Co., Whitehouse Station, NJ). Expres-
sion data were loaded into the Resolver (Rosetta proprietary
software database) for transformation, normalization, and error
modeling.Microarray data analysis
Microarray data from each individual liver or PBMC sample
was compared back to a reference pool composed of all corre-
sponding samples of liver or PBMC, respectively, from HCV
monoinfected subjects. HCV/HIV-coinfected gene sets were estab-
lished based on their statistically signiﬁcant up- or down-regula-
tion (absolute fold change Z1.15 and ANOVA or combined p-
value r01 in at least 7 samples) when compared to the reference
pool. Signature genes from each tissue were identiﬁed and
compared. Unsupervised clustering methods, including hierarch-
ical and k-means clustering, were performed to identify genes
with similar expression patterns. Ingenuity Pathway Analysis
(IPA; Ingenuity Systems, Redwood City, CA) software was used
for functional analysis of signiﬁcant genes identiﬁed by ANOVA.Immunoblotting
Patient plasma samples were diluted in M-PER (Thermo
Scientiﬁc, Rockford, IL) and protein concentration was quantiﬁed
by BCA assay (Thermo Scientiﬁc) per the manufacturer’s instruc-
tions. A Criterion TGX Any kD Tris-glycine polyacrylamide gel
(Bio-Rad, Hercules, CA) was loaded with 20 mg protein per
sample, run using standard SDS-PAGE methods, and transferred
to a PVDF membrane. Membranes were probed with anti-Reg1a
(Abcam, Cambridge, MA) and anti-Reg3a (Abcam) primary anti-
bodies, followed by peroxidase-conjugated donkey anti-rabbit
secondary (Jackson ImmunoResearch Labs, West Grove, PA), and
detected using ECL Plus reagent (GE Healthcare Biosciences).
There is no protein reported to be constitutively secreted at
similar levels in plasma or serum samples which could act as a
loading control, therefore protein loading per well was normal-
ized by loading equal quantities of protein per lane.Liver and PBMC network construction
Networks were constructed as described previously (Zhu et al.,
2004,2008) and were visualized using the Target Gene Informa-
tion (TGI) Network Analysis and Visualization (NAV) desktop
application developed at Rosetta Inpharmatics. We utilized pre-
viously published data sets for liver (Lamb et al., 2011; Schadt
et al., 2008; Zhong et al., 2010) and PBMC (Emilsson et al., 2008)
network constructions. To construct liver and PBMC networks
based on HCV/HIV coinfected gene signatures, the two gene
signatures were loaded into the database as described in the
results section and the TGI NAV tool was used to extract all edges
from this network involving the included signature genes of
interest.
The TGI NAV tool allows rapid, real-time, graphical analysis of
pathway network models built from a comprehensive and fully
integrated set of public and proprietary interaction databases
available through a back-end central database. In addition, it
supports experimentally generated systems biology data such as
the statistical associations and causal relationships described in
the manuscripts cited above and applied in the current study.Acknowledgments
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